Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem's portfolio of small molecule drugs inhibit critical signaling pathways in cancer including the PI3K and FAK pathways. These signaling pathways are aberrant in cancer and promote tumor survival. Preclinical research has shown that these pathways also contribute to the protective nature of the tumor microenvironment, thereby limiting the effectiveness of cancer treatments.
Verastem’s lead product candidate is duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. Duvelisib has successfully met its primary endpoint in a Phase 2 study in refractory indolent Non-Hodgkin's Lymphoma (NHL) and is currently being evaluated in a Phase 3 registration trial in patients with relapsed/refractory Chronic Lymphocytic Leukemia (CLL).
Other clinical product candidates include focal adhesion kinase (FAK) inhibitors VS-6063 and VS-4718, and dual PI3K/mTOR inhibitor VS-5584. VS-6063 is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma.